Flag of the European Union EU Clinical Trials Register Help

Clinical trials for McDonald criteria

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    274 result(s) found for: McDonald criteria. Displaying page 2 of 14.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-003134-14 Sponsor Protocol Number: PDY6045 Start Date*: 2007-06-04
    Sponsor Name:Sanofi-aventis U.S. Inc.
    Full Title: A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide...
    Medical condition: Multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-004519-43 Sponsor Protocol Number: NN18344 Start Date*: 2005-01-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Phase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple Sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Prematurely Ended) ES (Ongoing) DE (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005125-11 Sponsor Protocol Number: RCT-EPO-001 Start Date*: 2008-12-19
    Sponsor Name:Walton Centre for Neurology and Neurosurgery
    Full Title: A pilot single-centre randomised controlled trial of recombinant human erythropoietin versus placebo in primary progressive multiple sclerosis.
    Medical condition: Primary progressive multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063401 Primary progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-004903-39 Sponsor Protocol Number: WCNNMBJR001 Start Date*: 2005-07-26
    Sponsor Name:The Walton Centre for Neurology and Neurosurgery
    Full Title: A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs. Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis.
    Medical condition: Early, active relapsing remitting Multiple Sclerosis (RRMS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001340-22 Sponsor Protocol Number: BHT-3009-03 Start Date*: 2005-08-12
    Sponsor Name:Bayhill Therapeutics
    Full Title: BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS
    Medical condition: Multiple sclerosis results from an auto-immune reaction characterized by inflammation within the nervous system. Myelin basic protein is a target of the autoimmune response and is generally regarde...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FI (Prematurely Ended) SK (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004893-29 Sponsor Protocol Number: PDY6046 Start Date*: 2007-07-25
    Sponsor Name:Sanofi-aventis U.S. Inc.
    Full Title: A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide...
    Medical condition: Multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003384-30 Sponsor Protocol Number: IR902-231 Start Date*: 2007-02-26
    Sponsor Name:The Immune Response Corporation
    Full Title: A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for Multiple Sclerosis
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006323-39 Sponsor Protocol Number: SuniMS-03 Start Date*: 2007-06-19
    Sponsor Name:Charité-Universitätsmedizin Berlin
    Full Title: Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis
    Medical condition: relapsing-remitting multiple sclerosis ICD classification: G35.1
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000345-31 Sponsor Protocol Number: NL56584.092.16 Start Date*: 2016-09-30
    Sponsor Name:VU medical center
    Full Title: Towards personalized dosing of natalizumab in multiple sclerosis
    Medical condition: multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10070425 Multiple sclerosis exacerbation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005263-29 Sponsor Protocol Number: 25-01 Start Date*: 2006-01-31
    Sponsor Name:Gesellschaft fuer klinische Forschung e.V. (Society for Clinical Research) [...]
    1. Gesellschaft fuer klinische Forschung e.V. (Society for Clinical Research)
    2. WELEDA AG
    Full Title: Multiple Sclerosis and Extract of Cannabis (MUSEC): A randomised, double-blind, placebo-controlled phase III trial to determine the efficacy and safety of a standardised oral extract of Cannabis sa...
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005262-39 Sponsor Protocol Number: 2006-2209 Start Date*: 2007-05-30
    Sponsor Name:Charité-Universitätsmedizin Berlin
    Full Title: Flupirtin as Oral Treatment in MS
    Medical condition: Relapsing-remitting multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002785-20 Sponsor Protocol Number: EVIDIMS Start Date*: 2011-09-19
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis
    Medical condition: Multiple Sclerosis and Clinical isolated Syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005860-24 Sponsor Protocol Number: OmniaOMS Start Date*: 2022-10-28
    Sponsor Name:I.R.C.C.S. FONDAZIONE S.LUCIA
    Full Title: Multidimensional integrated assessment of neurological and immunological patterns to test the efficacy and response to Ozanimod in multiple sclerosis
    Medical condition: relapsing remitting multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002180-33 Sponsor Protocol Number: SMderpept Start Date*: 2016-11-16
    Sponsor Name:Centrum Neurologii Krzysztof Selmaj
    Full Title: Multiple sclerosis therapy with transdermal myelin peptide stimulation.
    Medical condition: relapsing-remitting multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003086-40 Sponsor Protocol Number: PIX001 Start Date*: 2008-04-08
    Sponsor Name:Fondation Charcot Stichting
    Full Title: A Phase I/II Study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS)
    Medical condition: aggressive relapsing remitting (RR) or secondary progressive (SP) multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002298-39 Sponsor Protocol Number: 15-PP-06 Start Date*: 2015-11-17
    Sponsor Name:CHU de Nice
    Full Title: A national, multi-center study to evaluate the safety of long term treatment with teriflunomide 14 mg once daily in patients with a first clinical episode suggestive of multiple sclerosis in a long...
    Medical condition: patient with Clinically isolated syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    18.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004579-22 Sponsor Protocol Number: GAM-25 Start Date*: 2008-10-14
    Sponsor Name:Octapharma AG
    Full Title: A prospective, multicentre, open label, exploratory study to investigate the ability of the Heidelberg Assay Panel and the B-Cell /Antibody response panel to predict the clinical effect of Octagam ...
    Medical condition: Subjects with RR Multiple Sclerosis in whom intravenous immunoglobulin (IVIG) treatment is clinically indicated because first-line treatments are contraindicated or not tolerated.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003600-40 Sponsor Protocol Number: 218MS305 Start Date*: 2014-09-15
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects w...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) LT (Completed) CZ (Completed) IT (Completed) FI (Completed) BG (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003927-12 Sponsor Protocol Number: DRI15928 Start Date*: 2019-03-06
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 2b dose-finding study for SAR442168, a Bruton's tyrosine kinase inhibitor, in participants with relapsing multiple sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) NL (Completed) SK (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020338-25 Sponsor Protocol Number: WA25046 Start Date*: 2010-11-02
    Sponsor Name:F.Hoffmann-La Roche
    Full Title: A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis
    Medical condition: Primary Progressive Multiple Sclerosis (PPMS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) ES (Ongoing) BE (Completed) FR (Completed) HU (Completed) NL (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed) PT (Completed) AT (Completed) FI (Completed) IT (Completed) GR (Completed) BG (Completed) DK (Prematurely Ended) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 15 23:59:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA